Yayın:
Targeting leukemic stem cells: enhanced eradication <i>via</i> tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives

Sadeleştirilmiş öğe sayfası
dc.contributor.authorSEVER, BELGİN
dc.contributor.authorNurcan Gümüş
dc.contributor.authorİlayda Alçıtepe
dc.contributor.authorCumhur Gündüz
dc.contributor.authorBelgin Sever
dc.contributor.authorHalil I. Ciftci
dc.contributor.authorGüray Saydam
dc.contributor.authorBurçin Tezcanlı Kaymaz
dc.contributor.orcid0000-0001-9989-4590
dc.contributor.orcid0000-0002-7548-9248
dc.contributor.orcid0000-0002-6593-3237
dc.contributor.orcid0000-0003-4847-9711
dc.contributor.orcid0000-0002-9796-7669
dc.contributor.orcid0000-0001-8646-1673
dc.contributor.orcid0000-0003-1832-1454
dc.date.accessioned2025-11-13T12:10:30Z
dc.date.issued2025-07-25
dc.identifier.doihttps://doi.org/10.1080/1120009x.2025.2532948
dc.identifier.endpage20
dc.identifier.issn1120-009X
dc.identifier.openalexW4412653839
dc.identifier.startpage1
dc.identifier.urihttps://hdl.handle.net/11421/9195
dc.identifier.urihttps://doi.org/10.1080/1120009x.2025.2532948
dc.language.isoen
dc.relation.ispartofJournal of Chemotherapy
dc.rightsrestrictedAccess
dc.subjectStem cell
dc.subjectPharmacology
dc.subjectIn silico
dc.subjectHaematopoiesis
dc.subjectCombination therapy
dc.subjectApoptosis
dc.subjectTyrosine-kinase inhibitor
dc.subjectCancer research
dc.subjectBiology
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectGene
dc.subjectBiochemistry
dc.subjectCell biology
dc.subject.sdg3
dc.titleTargeting leukemic stem cells: enhanced eradication <i>via</i> tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5040352588

Dosyalar

Koleksiyonlar

Publications